Classes
DEA Class; Rx
Common Brand Names; Navelbine
- Antineoplastics, Vinca Alkaloid
Description
Semi-synthetic vinca alkaloid; microtubule inhibitor
Used for the treatment of metastatic non-small cell lung cancer
Vesicant; closely monitor for signs and symptoms of extravasation
Indications
Indicated for metastatic non-small cell lung cancer (NSCLC)
Indicated in combination with cisplatin for first-line treatment of locally advanced or metastatic NSCLC
Adverse Effects
- Leukopenia (92%)
- Granulocytopenia (90%)
- Anemia (83%)
- Elev AST (67%)
- Nausea (44%)
- Asthenia (36%)
- Constipation (35%)
- Fatigue (27%)
- Peripheral neuropathy (25%)
- Vomiting (20%)
- Anorexia (20%)
- Stomatitis (20%)
- Alopecia (12%)
Warnings
Myelosuppression, manifested by neutropenia, anemia, and thrombocytopenia reported; neutropenia is the major dose-limiting toxicity; monitor complete blood counts before each dose
Risk of extravasation and tissue injury
Sensory and motor neuropathies reported
Can cause fetal harm if administered to pregnant women based on findings from animal studies and mechanism of action
Pregnancy and Lactation
Based on animal findings, can cause fetal harm when administered to pregnant women
Verify pregnancy status in females of reproductive potential before initiating
Data are not available regarding drug in human milk or effects on breastfed infant or milk production
Because of potential harm; advise women not to breastfeed during treatment and for 9 days after final dose
Maximum Dosage
30 mg/m2 IV.
30 mg/m2 IV.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Vinorelbine tartrate
injectable solution
- 10mg/1mL
- 50mg/5mL
